The types and frequencies of adverse events were consistent with the known safety profile of denosumab, which showed long-term disease control for patients with GCTB with unresectable and resectable tumours. Our results suggest that the overall risk to benefit ratio for denosumab treatment in patients with GCTB remains favourable.
Belzutifan showed meaningful antitumour activity in VHL disease-associated CNS haemangioblastomas that was sustained for more than 3 years of treatment. These results continue to support…
Jordan has become the first WHO Member State of the Eastern Mediterranean Region to join the Global Platform for Access to Childhood Cancer Medicines. The…
On Sept 25, 2024, the European Commission approved France’s bid to ban single-use or disposable e-cigarettes.
Scott Bratman (Princess Margaret Hospital, Toronto, ON, Canada) reported results from the multicentre, single-arm phase 2 EVADER trial in which patients with HPV-related oropharyngeal cell…
In more than a dozen years spent reviewing shows at the Edinburgh Festival Fringe, the world’s largest arts festival, I struggle to remember laughing quite…
Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel…
In view of its higher sensitivity than RMI1 at 250, despite some loss in specificity, we recommend that IOTA ADNEX at 10% should be considered…
These long-term results support METex14 as a targetable oncogenic driver in NSCLC and add to the evidence supporting capmatinib as a targeted treatment option for…
Ziftomenib showed promising clinical activity with manageable toxicity in heavily pretreated patients with relapsed or refractory acute myeloid leukaemia. Phase 2 assessment of ziftomenib combination…
The UK’s beleaguered National Health Service (NHS) was in sharp focus after publication of the eagerly awaited Darzi review on Sept 12, 2024. The review…
